{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_2093294_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"019-910-149-982-413","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10776,"type":"PATENT","title":"University of Zurich - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":3600,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8246,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"Uni* Zurich\"; \"Univ* Zuerich\"; \"Univ* Zuer*\"; \"Zuer* Uni*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2413
Search Applicants and Owners separately: \"Uni* Zurich\"; \"Univ* Zuerich\"; \"Univ* Zuer*\"; \"Zuer* Uni*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2413
(a) administering to a non-human animal an immunogenic amount of a fragment of human NogoA consisting of amino acids 132-939, or 206-501 of an amino acid sequence with more than 90% identity over the entire length of SEQ ID No:29 or consisting of an amino acid sequence of SEQ ID NO:29 corresponding to amino acids 623-640 of SEQ ID No:2 based on the alignment shown in Figure 13.
(b) producing monoclonal antibody molecules by continuous cell lines from said non-human animal in culture;
(c) recovering said monoclonal antibodies from the culture."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["A protein fragment of human NogoA consisting of amino acids 132-939, 206-501, or 501-680 of a sequence with more than 90% identity over the entire length of SEQ ID No:29, or consisting of an amino acid fragment of SEQ ID NO:29, corresponding to amino acids 623-640 of SEQ ID No:2, based on the alignment shown in Figure 13."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["An isolated nucleic acid that encodes the protein fragment of claim 11."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A cloning vector comprising the nucleic acid of claim 12 operably linked to a non-native promoter, wherein said vector is preferably an expression vector."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["A recombinant cell transformed with the vector of claim 13, which is preferably a prokaryotic or eukaryotic recombinant cell."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A method of producing the protein fragment of claim 11 comprising: (a) culturing the cell of claim 14; and (b) recovering said protein."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The protein fragment of claim 11 for use as a medicament."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["A ribozyme or an antisense nucleic acid that specifically inhibits the production of the human Nogo-A protein and specifically targets the mRNA region encoding the protein fragment of claim 11 in a subject."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["A ribozyme or an antisense nucleic acid of claim 12 for use as a medicament."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["Use of the protein fragment of claim 11, said protein fragment being active in inhibiting cell proliferation in a subject, for the manufacture of a medicament for treating a neoplastic disease of the central nervous system, preferably selected from the group consisting of: glioma, glioblastoma, medulloblastoma, craniopharyngioma, ependyorna, pineaioma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, neuroblsatoma, and retinoblastoma."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["Use of a ribozyme or antisense nucleic acid according to claim 17, for the manufacture of a medicament for treating damage to the central nervous centrum, for inducing regeneration of sprouting neurons, or for promoting plasticity of the central nervous system."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["A method for screening for agonists or antagonists of human NogoA with potential utility as neural growth promoters for drug development comprising the steps of:
a) providing a protein having a sequence with more than 90% identity over the entire length of SEQ ID No:29, or a human Nogo-A protein fragment according to claim 11,
b) adding a candidate molecule to said protein or fragment, and
c) detecting whether the candidate molecule binds to the protein or fragment,wherein the candidate molecules are obtained from random or combinatorial peptide libraries such as chemically synthesized libraries, phage display libraries or in vitro translation-based libraries; or non-peptide libraries such as benzodiazepine libraries, peptoid libraries or a library in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library."],"number":21,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}